ERI Newsletter - November 2024?
Eyerising International
Introducing repeated low-level red-light therapy for myopia control. *Content for healthcare practitioners only.
We are pleased to announce the launch of our monthly clinical newsletter, where we will bring you the latest updates on RLRL. Thanks so much for being here, and we look forward to sharing many more exciting developments with you!
Note: The following newsletter is for eye care professionals only.
Clinical updates
We would love to have you at our upcoming MiVision CPD webinar on November 20th on RLRL, open to clinicians around the world. Hear from Dr Stojanovic (Norway) about his European results, Dr. FERNANDO FERNANDEZ VELAZQUEZ (Spain) on his trial of adjunct orthokeratology and RLRL, and Dr Igarashi-Yokoi (Japan) on her recently completed trial with Professor Kyoko Ohno-Matsui of RLRL in high myopia.
Register using the link above, and we can’t wait to see you there!
We recently completed a series of interviews with Dr. Kate Gifford of Myopia Profile where she spoke to experts from around the world – Japan, Australia, Poland, China and more! She also interviewed Dr. Karl Schulmeister, a leading laser expert from Austria, on his testing of the Eyerising device. You can find the article about these interviews and with their highlights here, as well as full copies of each interview on our website here.
A big thank you to Kate and the Myopia Profile team!
A key advantage of RLRL is its impressive results in high myopia, as this recently published RCT in the American Journal of Ophthalmology demonstrates. Unlike any other myopia control intervention, RLRL shows even stronger effect in highly myopic children, with 59% of these children showing significant axial shortening in 12 months. Read our summary here or the full paper here.
In case you missed it, Dr. Jagrut Lallu recently published an article in NZ Optics covering a series of case studies of RLRL. Read all about them here, and a big thank you to Dr. Lallu for sharing his insights!?
Did you know??
Although the Eyerising device was only introduced internationally last year, it has been used in China now for over 8 years. Over this time, there have been 160,000+ historical users and currently, 110,000 users log in daily for their RLRL treatment. This includes 15,000+ that have been on the device for over 3 years, and 1500+ that have been using it for over 5 years!
Q&A and feedback welcome!
In this section, we will be providing answers to some of our most asked questions on RLRL. If you have any questions or feedback for us, please feel free to send them through to [email protected] or message us on LinkedIn, and we will respond to you and possibly feature your question in a future newsletter.
Q: Why can’t we use atropine with RLRL?
A: As atropine is a mydriatic drug and causes pupil dilation, it is a contraindication to use it together with RLRL as we cannot be sure of the amount of power entering the eye. This adjunct use is being further investigated by Professor Jason Yam of CUHK in his LAMP3 trial, and we hope to have more developments on this front soon. In the meantime, if you wish to switch a patient on atropine to RLRL, please ensure a 2-week washout period before commencing RLRL.?
500 patients achieved!
Finally, we are pleased to announce that we have reached 500 patients internationally outside of China! Thank you so much to all our clinicians and patients for trusting and believing in RLRL.
Thank you once again for your interest in RLRL, and check in with you again soon!
The Eyerising International Team
Clinical Optometrist, Educator, Author, Clinical Applications Specialist (CAS), Founder & Director at Mero Eye Foundation-Nepal
3 个月Hi team, since long I haven't gotten a response from you. Can you please contact me?